Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis combats...

    Novartis combats eyecare, heart drug fallout with older drugs

    Written by savita thakur thakur Published On 2016-04-22T12:02:38+05:30  |  Updated On 22 April 2016 12:02 PM IST

    Zurich : A strong performance by its older medicines helped Novartis beat profit forecasts on Thursday, making up for its struggling eyecare business and the extra costs of a poor start for a new heart failure drug.


    Although the world's biggest prescription drugmaker's first-quarter core net income fell 13 percent to $2.79 billion, it beat the $2.76 billion average of estimates from analysts polled by Reuters and lifted the company's shares.


    Novartis was forced to hire more sales people to get over the slow take-up of new heart failure drug Entresto, just one of the challenges facing chief executive Joe Jimenez.


    The other main difficulties facing Jimenez include blood cancer drug Gleevec's exposure to generics in the United States and the revenue slide at its Alcon eyecare business.


    Core operating profit at Novartis fell 11 percent in dollars to $3.26 billion, but was down just 5 percent at constant exchange rates. The company said that left its 2016 forecast for sales and core operating profit broadly in line with last year's within its reach.


    "As expected, our results reflect additional investments behind our new launches and Alcon," Jimenez said in a statement.


    "We are on track with the plan we outlined in January to further focus our divisions, drive greater innovation and significant synergies and productivity," he added


    Revenue fell to $11.6 billion, lagging the poll average of $11.8 billion, despite better-than-expected sales of blockbuster blood cancer drug Gleevec, whose 22 percent decline to $834 million beat analyst forecasts of a 34 percent fall.


    It also got help from psoriasis medicine Cosentyx, whose sales rose to $176 million from $22 million a year earlier.


    SLOW LAUNCH CONTINUES


    Entresto posted just $17 million in sales and for the full year, Novartis now expects just $200 million in sales, or less than half of consensus forecasts compiled by Thomson Reuters Cortellis.

    Consequently, Novartis is expanding Entresto's U.S. sales force and doubling down on direct-to-consumer ads.


    "The slow launch of Entresto continues," Berenberg analysts wrote in a note to investors.


    Alcon sales fell 7 percent to $1.4 billion. Its 17 percent operating margin was worse than consensus forecasts of 20 percent, wrote Deutsche Bank analyst Tim Race.


    "It appears a low-quality beat and the continued undershooting of Entresto and Alcon could offset the initial positivity," he said.


    Shares initially rose by 1.3 percent, but tapered gains to trade 0.7 percent higher at 0838 GMT, trimming their fall this year to 14 percent.


    (Editing by Michael Shields and Alexander Smith)

    AlconAlexander Smithblood cancereyecareheart drugsJoe JimenezMichael ShieldsNovartis
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok